NEW YORK, March 13, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Perrigo Company (NYSE: PRGO), Zoetis Inc. (NYSE: ZTS), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), GlaxoSmithKline plc (NYSE: GSK), and AstraZeneca plc (NYSE: AZN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
--
Perrigo Company Analyst Notes
On February 28, 2014, Perrigo Company (Perrigo) reported its acquisition of a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global Inc. for $51 million in cash. According to the Company, the acquired products include Herron® range of analgesics, vitamins and supplements, and are expected to generate at least $20 million in annual revenue. Perrigo's Chairman, President and CEO, Joseph C. Papa said, "The acquisition of OTC products in Australia enhances our position by broadening our product offering and increasing our relevance with the mass retail customers. This deal furthers our strategy to expand our Consumer Healthcare portfolio internationally, while making quality products more affordable for consumers and customers around the world." The full analyst notes on Perrigo Company are available to download free of charge at:
http://www.AnalystsReview.com/03132014/PRGO/report.pdf
--
Zoetis Inc Analyst Notes
On March 4, 2014, Zoetis Inc (Zoetis) announced that it has appointed Dr. Wille M. Reed to its Board of Directors. According to the Company, in his new role, Dr. Reed will serve on the Corporate Governance Committee of the Board. Dr. Reed serves as the Dean of the College of Veterinary Medicine at Purdue University, and has more than 30 years of experience in animal health and veterinary medicine. The Company stated that as a recognized expert in avian pathology, diagnostic medicine and infectious diseases, Dr. Reed brings perspectives on veterinary medicine that will be crucial as Zoetis continues to enhance its reputation as a world leader in animal health. The Company believes that Dr. Reed will add valuable scientific expertise to the Zoetis Board, as well as a unique understanding of the needs of Zoetis customers and the animals that depend on the company's medicines and vaccines. The full analyst notes on Zoetis Inc are available to download free of charge at:
http://www.AnalystsReview.com/03132014/ZTS/report.pdf
--
ISIS Pharmaceuticals, Inc. Analyst Notes
On March 6, 2014, ISIS Pharmaceuticals, Inc. (ISIS) announced its participation at the upcoming Barclays Global Healthcare Conference. The Company informed that the conference will take place on Thursday, March 13, 2014 at 9:00 a.m. ET in Miami, Florida. According to the Company, interested parties can view the live webcast of the presentation on the "Investors & Media" section of ISIS' website. The full analyst notes on ISIS Pharmaceuticals, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03132014/ISIS/report.pdf
--
GlaxoSmithKline plc Analyst Notes
On March 9, 2014, GlaxoSmithKline plc (GSK) announced that the Company has successfully increased its stake in its publicly-listed pharmaceuticals subsidiary in India, GlaxoSmithKline Pharmaceuticals Limited, from 50.7% to 75% following the voluntary Open Offer undertaken by its subsidiary, GlaxoSmithKline Pte Ltd. David Redfern, Chief Strategy Officer, GSK, said, "We are very pleased with the outcome of this transaction, which further increases our exposure to a strategically important market. It is a significant vote of confidence in the future growth prospects of our Pharmaceuticals business in India and underlines GSK's long-standing commitment to the country." The full analyst notes on GlaxoSmithKline plc are available to download free of charge at:
http://www.AnalystsReview.com/03132014/GSK/report.pdf
--
AstraZeneca plc Analyst Notes
On March 3, 2014, AstraZeneca plc (AstraZeneca) announced that its BYDUREON® Pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes, has been approved by the U.S. Food and Drug Administration (FDA). According to the Company, BYDUREON is the first and only once-weekly medicine for adults with type 2 diabetes, and is a pre-filled, single-use pen injector, eliminating the need for the patient to transfer the medication between a vial and syringe during the self-injection process. AstraZeneca informed that the BYDUREON Pen contains the same formulation and dose as the original BYDUREON single-dose tray, providing the same continuous release of exenatide. The full analyst notes on AstraZeneca plc are available to download free of charge at:
http://www.AnalystsReview.com/03132014/AZN/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
